Sanofi Consumer Healthcare India operates in the pharmaceuticals sector, focusing on consumer healthcare products. With a market cap of ₹10,223 Cr and quarterly revenues around ₹230 Cr, it is a mid-cap player in Indian consumer pharma. The company demonstrates strong profitability with a 35%+ operating margin.
Generated analysis · source review pending
Generated analysis · source review pending
504 historical price candles were omitted because the exchange source has not been verified.
No red flags triggered.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Documents link to external sources (exchange filings, company investor pages).
Consolidated figures
| Ratio | Mar 2023 | Mar 2024 |
|---|---|---|
| Margins | ||
| Gross margin % | 72.7% | 74.3% |
| EBITDA margin % | 39.4% | 37.4% |
| EBIT margin % | 39.1% | 36.7% |
| PAT margin % | 29.7% | 25% |
| Working capital | ||
| Receivable days | — | — |
| Inventory days | — | — |
| Payable days | — | — |
| NWC days | — | — |
| Leverage | ||
| Current ratio | — | — |
| Debt to EBITDA | — | — |
| Debt to equity | — | — |
| Interest coverage | — | 71.6 |
| Asset turnover | — | — |
| Return ratios | ||
| Return on assets % | — | — |
| Return on capital employed % | — | — |
| Return on equity % | — | — |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
| Holder (%) | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| 60.4% | 60.4% | 60.4% | 60.4% | 71.27% | 71.27% | 71.27% | 71.27% | 71.27% | |
| 6.03% | 5.22% | 4.42% | 4.53% | 3.24% | 2.94% | 2.83% | 2.76% | 2.6% | |
| 22.81% | 24.03% | 25.35% | 25.48% | 16.89% | 17.21% | 17.33% | 17.57% | 17.86% | |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10.76% | 10.35% | 9.83% | 9.59% | 8.6% | 8.58% | 8.57% | 8.4% | 8.27% | |
| No. of shareholders | — | — | — | — | — | 48,808 | 48,075 | 48,418 | 47,511 |
Promoter holding up 10.87 percentage points since Jun 2024.
| Date | Client | Type | Venue | Side | Quantity | Price | Value |
|---|---|---|---|---|---|---|---|
| 10 Oct 2024 | OPELLA HEALTHCARE PARTICIPATIONS B V | Block | BSE | Buy | 1,39,04,722 | ₹4,982.05 | ₹6,927.40 Cr |
| 10 Oct 2024 | HOECHST GMBH | Block | BSE | Sell | 1,39,04,722 | ₹4,982.05 | ₹6,927.40 Cr |
| 10 Oct 2024 | OPELLA HEALTHCARE PARTICIPATIONS B V | Bulk | BSE | Buy | 1,39,04,722 | ₹4,982.05 | ₹6,927.40 Cr |
| 10 Oct 2024 | HOECHST GMBH | Bulk | BSE | Sell | 1,39,04,722 | ₹4,982.05 | ₹6,927.40 Cr |
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM | ₹1,61,325 Cr | ₹1,76,123 Cr | ₹15,723 Cr | ₹5,191 Cr | 32.6% | ₹2,181 Cr | 15.3% | 14.5% | 27.1% | 163 |
| Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE | ₹1,14,284 Cr | ₹1,26,053 Cr | ₹28,592 Cr | ₹8,316 Cr | 31.2% | ₹4,513 Cr | 18.9% | 23.4% | 19.7% | 212 |
| Laurus Labs LimitedLAURUSLABSLAURUSLABS | ₹1,07,176 Cr | ₹1,09,573 Cr | ₹7,270 Cr | ₹2,034 Cr | 26.1% | ₹1,093 Cr | 13.1% | 21.3% | 18.2% | 263 |
| Mankind Pharma LimitedMANKINDMANKIND | ₹1,04,696 Cr | ₹1,11,007 Cr | ₹14,738 Cr | ₹3,827 Cr | 25.3% | ₹2,068 Cr | 13.6% | 14.2% | 12.5% | 117 |
| Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA | ₹97,389 Cr | ₹1,05,065 Cr | ₹34,935 Cr | ₹7,085 Cr | 20.3% | ₹3,713 Cr | 10.4% | 14.7% | 9.9% | 252 |
| Lupin LimitedLUPINLUPIN | ₹92,866 Cr | ₹98,777 Cr | ₹29,967 Cr | ₹9,538 Cr | 31.5% | ₹5,529 Cr | 19.2% | 34.2% | 26.9% | 181 |
| Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK | ₹65,781 Cr | ₹65,781 Cr | ₹17,737 Cr | ₹4,797 Cr | 26.9% | ₹1,496 Cr | 8% | 37.8% | 0% | 83 |
| Alkem Laboratories LimitedALKEMALKEM | ₹62,431 Cr | ₹64,055 Cr | ₹15,081 Cr | ₹3,032 Cr | 20.4% | ₹2,158 Cr | 16% | 21.5% | 17.8% | 152 |
| Biocon LimitedBIOCONBIOCON | ₹60,413 Cr | ₹75,238 Cr | ₹17,321 Cr | ₹3,536 Cr | 20.4% | ₹495 Cr | 2.2% | 3.9% | 1.4% | 85 |
| Abbott India LimitedABBOTINDIAABBOTINDIA | ₹56,901 Cr | — | ₹4,310 Cr | ₹921 Cr | 27.3% | ₹691 Cr | 22.4% | 44.1% | 34.5% | 110 |
| Ipca Laboratories LimitedIPCALABIPCALAB | ₹49,299 Cr | ₹50,003 Cr | ₹10,126 Cr | ₹2,232 Cr | 20.5% | ₹1,310 Cr | 12.3% | 17.8% | 15.2% | 308 |
| Gland Pharma LimitedGLANDGLAND | ₹47,428 Cr | ₹47,671 Cr | ₹6,725 Cr | ₹1,751 Cr | 25.3% | ₹1,129 Cr | 16% | 14.8% | 10.5% | 255 |
23 schemes · 8 fund houses
| Shares | ||||||
|---|---|---|---|---|---|---|
| Growth Mid Cap FundNEW | Nippon India Mutual Fund | 4.41 L | 182.74 | 0.35% | 1.919% | — |
| SMALL CAP FUND | Nippon India Mutual Fund | 2.73 L | 112.84 | 0.14% | 1.185% | -0 |
| Multi Cap FundNEW | Nippon India Mutual Fund | 2.72 L | 112.57 | 0.2% | 1.182% | — |
| PHARMA FUND | Nippon India Mutual Fund | 2.14 L | 88.46 | 0.93% | 0.929% | -0 |
| Small Cap FundNEW | ICICI Prudential Mutual Fund | 1.83 L | 75.7 | 0.77% | 0.795% | — |
| Dividend Yield Fund | SBI Mutual Fund | 1.77 L | 73.08 | 0.85% | 0.767% | -13,048 |
| Healthcare FundNEW | ICICI Prudential Mutual Fund | 1.65 L | 68.12 | 0.97% | 0.715% | — |
| Innovation Fund | Nippon India Mutual Fund | 96,605 | 40 | 1.29% | 0.42% | -0 |
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Results - Financial Results For June 30, 2026
Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, 28Th July 2026
Board Meeting Intimation For Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2026.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
| Date | Category | Subject | Filing |
|---|---|---|---|
| 28 Sept 2026, 5:36 pm | Insider Trading / SAST Closure of Trading Window | Closure of Trading Window | |
| 30 Jul 2026, 12:50 pm | Company Update Newspaper Publication | Announcement under Regulation 30 (LODR)-Newspaper Publication |
| 28 Jul 2026, 8:04 pm | Company Update Press Release / Media Release | Announcement under Regulation 30 (LODR)-Press Release / Media Release |
| 28 Jul 2026, 7:52 pm | Result Financial Results | Results - Financial Results For June 30, 2026 |
| 28 Jul 2026, 7:41 pm | Board Meeting Outcome of Board Meeting | Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, 28Th July 2026 |
| 22 Jul 2026, 5:06 pm | Board Meeting | Board Meeting Intimation For Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2026. |
| 9 Jul 2026, 3:41 pm | Company Update Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 |
| 29 Jun 2026, 9:38 pm | Company Update Appointment of Statutory Auditor/s | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s |
Consolidated figures · ₹ crore
| ₹ Cr | Mar 2023 | Mar 2024 |
|---|---|---|
| 555 | 725 | |
| COGS | 152 | 186 |
| Gross profit | 404 | 538 |
| 185 | 268 | |
| Operating profit (EBITDA) | 219 | 271 |
| OPM % | 39.4% | 37.4% |
| Depreciation | 2 | 5 |
| Interest | 0 | 4 |
| 2 | -15 | |
| Profit before tax | 219 | 247 |
| Tax | 54 | 66 |
| Tax % | 24.8% | 26.7% |
| 165 | 181 | |
| PAT margin % | 29.7% | 25% |
| EPS (₹) | — | — |
| Annual report | — | Annual report for Mar 2024 |